Form D · Other

Front Range Biosciences, Inc.

Lafayette, CO · CIK 0001689059

Offering snapshot reported Feb 14, 2020 · SEC filing

Reported sold
$18.7M
Offering amount: $40.3M
Investors reported
55
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Jan 31, 2020
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Feb 14, 2020Initial$18,746,174No comparison55SEC filing
Sep 18, 2019Initial$8,500,000No comparison55SEC filing
Oct 4, 2018Initial$15,878,905No comparison87SEC filing
Jun 21, 2017Initial$372,500No comparison12SEC filing
Mar 3, 2017Amendment$1,492,500$785,000vs Nov 15, 201626SEC filing
Nov 15, 2016Initial$707,500No comparison6SEC filing
Nov 15, 2016Initial$10,000No comparison1SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-360645

Source: Form D, filed Feb 14, 2020. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Nicholas Hofmeister Director, Executive
Nick Hofmeister Director, Executive
Ephraim Lindenbaum Director
William Militello Director
Marc Riiska Director
Jonathan Vaught Director, Executive
Douglas Wolford Director
Christopher Zalewski Promoter

Issuer details

Industry: Other (See others in industry)

Address:
1724 Majestic Dr. #109 B
Lafayette, CO, 80026